WHY DOES PREECLAMPSIA TRANSFORM INTO HELLP SYNDROME? THE ROLE OF THE COMPLEMENT SYSTEM


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Consideration of the clinical manifestations of severe preeclampsia (PE) and HELLP syndrome in the context of thrombotic microangiopathy allows a fresh look at the pathogenesis of these gestational complications. There is new evidence for a similar mechanism for endothelial damage in severe PE, HELLP syndrome, and atypical hemolytic uremic syndrome (aHUS), which is realized due to the excessive activation of the alternative complement pathway. An investigation of the role of complement factors in the pathogenesis, course and progression of PE with realization in the HELLP syndrome will be able to further consider them as markers for predicting severe PE complications.

Texto integral

Acesso é fechado

Sobre autores

Alexander STRIZHAKOV

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Academician of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Elena TIMOKHINA

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

D.Sci. (Medicine), Professor of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Irina FEDYUNINA

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

Email: irina.fedjunina@mail.ru
assistant of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Irina IGNATKO

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

D.Sci. (Medicine), Professor of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Alexander ASLANOV

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

assistance of professor of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Irina BOGOMAZOVA

I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

assistance of professor of the Department of Obstetrics, Gynecology and Perinatology of the Medical Faculty Moscow, Russia

Bibliografia

  1. Гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Преэклампсия. Эклампсия. Клинические рекомендации МЗ России (протокол лечения). М.; 2016.
  2. Тимохина Е.В., Стрижаков А.Н., Белоусова В.С., Асланов А.Г., Богомазова И.М., Афанасьева Н.В., Самойлова Ю.А., Ибрагимова С.М., Кечина А.М. HELLP-синдром как жизнеугрожающее состояние: современные особенности течения. Акушерство, гинекология и репродукция. 2019; 13(1): 35-42.
  3. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Акиньшина С.В. Тромботические микроангиопатии в акушерской практике. М.: ГЭОТАР-Медиа; 2017. 304 с.
  4. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am. J. Obstet. Gynecol. 1982; 142(2): 159-67.
  5. Стрижаков А.Н., Тимохина Е.В., Пицхелаури Е.Г., Белоусова В.С., Якушина Н.И. Преэклампсия сегодня: патогенез и возможности прогнозирования и лечения. Вопросы гинекологии, акушерства и перинатологии. 2016; 15(3): 24-31.
  6. Стрижаков А.Н., Тимохина Е.В., Федюнина И.А., Игнатко И.В., Асланов А.Г., Тернова Д.Ю., Пицхелаури Е.Г. Биохимические маркеры поражения печени при HELLP-синдроме. Вопросы гинекологии, акушерства и перинатологии. 2019; 18(4): 59-65.
  7. Стрижаков А.Н., Игнатко И.В., Тимохина Е.В. Имитаторы тяжелой преэклампсии: вопросы дифференциальной диагностики и мультидисциплинарного ведения. Акушерство, гинекология и репродукция. 2019; 13(1): 70-8.
  8. Стрижаков А.Н., Тимохина Е.В., Игнатко И.В., Проценко Д.Н., Трощанский Д.В., Афанасьева Н.В., Ибрагимова С.М. Тромботическая микроангиопатия как проявление тяжелой преэклампсии и HELLP-синдрома. Вопросы гинекологии, акушерства и перинатологии. 2017; 16(6): 89-92.
  9. Батюшин М.М. Атипичный гемолитико-уремический синдром при беременности и HELLP-синдром. Вопросы дифференциальной диагностики. Клиническая нефрология. 2015; 3(1): 46-51.
  10. Шахиджанов С.С., Филиппова А.Е., Бутылин А.А., Атауллаханов Ф.И. Современное представление о системе комплемента. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2019; 18(3): 130-44.
  11. Alrahmani L., Willrich M.A. The complement alternative pathway and preeclampsia. Curr. Hypertens. Rep. 2018; 20(5): 40. https://dx.doi.org/10.1007/ s11906-018-0836-4.
  12. Vaught A.J., Gavriilaki E., Hueppchen N., Blakemore K., Yuan X., Seifert S.M., Brodsky R.A. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp. Hematol. 2016; 44(5): 390-8. https://dx.doi.org/10.1016/j.exphem.2016.01.005.
  13. Vaught A.J., Braunstein E.M., Jasem J., Yuan X., Makhlin I., Eloundou S. et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2019; 3(6): 46-57. pii: 99128. https://dx.doi. org/10.1172/jci.insight.99128.
  14. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/ HELLP syndrome. Placenta. 2013; 34(2): 201-3. : https://dx.doi.org/10.1016Zj. placenta.2012.11.014.
  15. McNamara L.A., Topaz N., Wang X., Hariri S., Fox L., MacNeil J.R. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb. Mortal. Wkly Rep. 2017; 66(27): 734-7. https://dx.doi.org/10.15585/mmwr.mm6627e1.
  16. Collier A.R., Pernicone E., Zsengeller Z., Salahuddin S., Khankin E., Karumanchi S.A. Placental sFlt1 and complement activation in preeclampsia and HELLP syndrome. Am. J. Obstet. Gynecol. 2018; 211(1): S195-6. https:// dx.doi.org/10.1016/j.ajog.2017.10.245.
  17. Yonekura Collier A.R., Zsengeller Z., Pernicone E., Salahuddin S., Khankin E.V., Karumanchi S.A. Placental sFLT1 is associated with complement activation and syncytiotrophoblast damage in preeclampsia. Hypertens. Pregnancy. 2019; 38(3): 193-9. https://dx.doi.org/10.1080/10641955.2019.1640725.
  18. Burwick R.M., Fichorova R.N., Dawood H.Y., Yamamoto H.S., Feinberg B.B. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2015; 62(6): 1040-5. https://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01420.
  19. Burwick R.M., Velâsquez J.A., Valencia C.M., Gutiérrez-Mann J., Edna-Estrada F., Silva J.L. et al. Terminal complement activation in preeclampsia. Obstet. Gynecol. 2018; 132(6): 1477-85. https://dx.doi.org/10.1097/ AOG.0000000000002980.
  20. Сидорова И.С., Никитина Н.А. Преэклампсия как гестационный иммунокомплексный комплементопосредованный эндотелиоз. Российский вестник акушера-гинеколога. 2019; 19(1): 5-11.
  21. Salmon J.E., Heuser C., Triebwasser M., Liszewski M.K., Kavanagh D., Roumenina L., Atkinson J.P. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2016; 8(3): e1001013. https://dx.doi.org/10.1371/journal.pmed.1001013.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies